The Week in Weed: February 27, 2026 – Lexology Insights
Acute cannabis effects include perceptual, cardiovascular, and cognitive changes that are time-limited but clinically important. Understanding these effects helps clinicians counsel patients effectively during therapy initiation. This knowledge supports…
Ghana Launches Regulated Medicinal Cannabis Programme
Ghana medicinal cannabis programme marks a significant regulatory milestone in West Africa. This programme enables generation of population-specific clinical data for cannabis therapeutics. It strengthens the global evidence base through structured…
The Role of the Endocannabinoid System in Placebo Analgesia
The endocannabinoid system placebo analgesia plays a key role in mediating pain relief by combining expectation and cannabinoid signaling. This mechanism suggests that both pharmacological and psychological factors contribute to analgesia. Understanding…
In the Mix: 12 More Articles — February 27, 2026
This collection reviews 12 cannabis articles that fall below the cannabis clinical relevance threshold as of February 27, 2026. These articles provide insights into emerging cannabis research areas and clinical trends. Understanding the cannabis clinical…
Nebraska Bill Seeks to Shield Doctors Recommending Medical Cannabis
The Nebraska medical cannabis program is progressing with legislation aimed at protecting physicians who recommend cannabis. This legal protection removes barriers for doctors, allowing them to provide evidence-based recommendations without fear of…
“Mother of Cannabinoids”: The Rising Potential of CBG and CBG-A
Cannabigerol anxiety cognitive symptoms are gaining attention as potential targets for new cannabinoid therapies. Patients not responding to CBD or THC may find promise in CBG formulations. Clinical evidence is preliminary but growing in this area.
Bridging the Gap: Medical Cannabis, Regulators, and Clinical Accountability
Medical cannabis prescribing accountability is essential for patient safety and regulatory compliance. Physicians must meet clinical standards identical to other controlled substances. This ensures evidence-based decision-making and ongoing patient…
Study Links Prenatal Cannabis Exposure to Schizophrenia Risk
Emerging research on prenatal cannabis exposure schizophrenia risk reveals biological signatures in placental tissue linked to increased schizophrenia risk in offspring. The placenta mediates fetal neurodevelopment during critical brain formation…
Daily Digest: Last 24 Hours: Adolescent Brain Risk, Cannabis and Mood Disorders, and Regulatory Growing Pains — February 27, 2026
This cycle’s coverage highlights psychiatric vulnerability adolescent cannabis risks, emphasizing young brains exposed to high-potency THC. Cannabis use links to anxiety and depression require careful interpretation. Regulatory decisions may undermine…
New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery
The Poland medical cannabis market has shown resilience following regulatory changes requiring in-person consultations. This shift temporarily limited access for patients who used telemedicine. The market's recovery highlights sustained patient demand…
